title: Not FDA-approved, but experts recommend Depo-Provera.
mesh_terms: D000569:Americas; D001943:Breast Neoplasms; D003257:Consumer Product Safety; D003267:Contraception; D003268:Contraception Behavior; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003695:Delivery of Health Care; D019049:Developed Countries; D004194:Disease; D011307:Drug Prescriptions; D005069:Evaluation Studies as Topic; D005193:Family Planning Services; D006285:Health Planning; D007878:Legislation as Topic; D017258:Medroxyprogesterone Acetate; D009369:Neoplasms; D009656:North America; D009934:Organization and Administration; D018570:Risk Assessment; D014481:United States
chemical_list: D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D017258:Medroxyprogesterone Acetate
keywords: Americas; Breast Cancer; Cancer; Contraception; Contraceptive Agents, Female--beneficial effects; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--beneficial effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--beneficial effects; Contraceptive Agents--side effects; Contraceptive Effectiveness; Contraceptive Usage--cost; Critique; Depo-provera--beneficial effects; Depo-provera--side effects; Developed Countries; Diseases; Distributional Activities; Evaluation; Family Planning; Legislation; Medroxyprogesterone Acetate--beneficial effects; Medroxyprogesterone Acetate--side effects; Neoplasms; North America; Northern America; Organization And Administration; Prescriptions--legal aspects; Product Approval; Program Activities; Programs; Risk Assessment; United States